

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

Le A 33 535

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

09/980,242

INTERNATIONAL APPLICATION NO.  
PCT/EP00/04431INTERNATIONAL FILING DATE  
16 May 2000 (16.05.00)PRIORITY DATE CLAIMED  
29 May 1999 (29.05.99)TITLE OF INVENTION **SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS  
ADENOSINE UPTAKE INHIBITORS**

APPLICANT(S) FOR DO/EO/US

**BISCHOFF, et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: 1) **Response to Notification of Missing Requirements;**  
2) **Copy of Notification of Missing Requirements; and**  
3) **Return Receipt Postcard.**

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8  
The undersigned hereby certifies that this paper and any papers referred  
to as attached is/are being deposited with the United States Postal  
Service, with sufficient postage, as first class mail in an envelope  
addressed to the Assistant Commissioner for Patents, Washington, D.C.  
20231 on this 21<sup>st</sup> day of APRIL, 2002

Signature of Person Mailing

21. ☐ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... **\$1000.00**International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... ~~\$860.00~~  
**\$890.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$710.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$690.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00****ENTER APPROPRIATE BASIC FEE AMOUNT =**Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =		x <b>\$18.00</b>
Independent claims	- 3 =		x <del>\$80.00</del> <b>\$4.00</b>
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <del>\$270.00</del> <b>\$280.00</b>

**TOTAL OF ABOVE CALCULATIONS =**☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2. +**SUBTOTAL =**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).**TOTAL NATIONAL FEE =**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +**TOTAL FEES ENCLOSED =**

Amount to be refunded:	\$
charged:	\$

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. **13-3372** in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. **13-3372**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**Jeffrey M. Greenman**  
Vice President, Patents and Licensing  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

SIGNATURE

**William F. Gray**

NAME

**31,018**

REGISTRATION NUMBER

Attorney Docket No. Le A 33 535

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Erwin Bischoff, et al.

Group Art Unit:

Serial No.: 09/980,242

Examiner:

Filed: 04/07/97

For: Substituted Phenylcyclohexane Carboxylic Acid Amides and Their Use as Adenosine Uptake Inhibitors

**BOX PCT**  
Assistant Commissioner for Patents  
Washington, DC 20231

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 12, 2002

*Beatriz Alviz*  
Beatriz Alviz

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS**

Sir:

This is in response to the Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office mailed to Applicants on 14 February 2002. A copy of the Notification of Missing Requirements is enclosed.

The Notification of Missing Requirements indicates that Applicants must provide:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing"
- An initial or substitute paper copy or compact disc of the "Sequence Listing", as well as an amendment directing its entry into the specification.

Applicants wish to clarify for the record that the present application does not contain a nucleotide and/or amino acid sequence disclosure, and therefore, it is not applicable to comply with the requirements for such disclosure pursuant to 37 C.F.R. 1.821-1.825.

Applicants respectfully request the withdraw of the Notification of Missing Requirements, and accordance of 29 November 2001 as the date of receipt of all 35 U.S.C. 371 requirements.

Respectfully submitted,

Date: April 12, 2002

Registration No. 31,018

Phone: (203) 812-2712

*William F. Gray*  
William F. Gray  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516-4175